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Liddle’s Syndrome (LS) is considered a rare Mendelian hypertension. We have 
previously described three reportedly unrelated families, native of an Italian area around 
the Strait of Messina, carrying the same mutation (βP617L) of the epithelial sodium 
channel.  
The aims of our study were: 1) to evaluate whether a close genomic relationship exists 
between the three families through the analysis of mitochondrial DNA (mtDNA) and Y 
chromosome; 2) to quantify the genomic relatedness between the LS patients belonging 
to the three families and assess the hypothesis of a mutation shared through Identity By 
Descent (IBD). 
The hypervariable region HVRI of the mtDNA genome and the Y chromosome short 
tandem repeats profiles were analysed in individuals of the three families. Genotyping 
542,585 genome-wide SNPs was performed in all the LS patients of the three families 
and some of their relatives. A panel of 780 healthy Italian adult samples typed for the 
same set of markers was used as controls. 
Despite different lineages between the three families based on the analysis of mtDNA 
and Y chromosome, the three probands and their six affected relatives share the same 
~5Mbp long haplotype which encompasses the mutant allele. Using an approach based 
on coalescent theory we estimate that the three families inherited the mutant allele from 
a common ancestor ~13 generations ago, and that such an ancestor may have left around 
20 carriers alive today.  
The prevalence of LS in the region of origin of the three families may be much higher 
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INTRODUCTION 
First described by Grant Liddle in 1963, LS is a hereditary condition, transmitted in an 
autosomal-dominant mode [1]. Its main clinical features include early onset of salt-
sensitive hypertension, increased incidence of premature cardio- and cerebro-vascular 
events, hypokalaemic metabolic alkalosis, suppression of both renin and aldosterone 
secretion, and unresponsiveness to mineralocorticoid receptor (MR) antagonists, as 
opposed to the response to epithelial sodium channel (ENaC) inhibitors (i.e., amiloride 
and triamterene) [1-3]. Patients with LS are most often diagnosed between 10 to 30 
years of age, but diagnosis is sometimes made earlier. LS occurs worldwide, with no 
apparent ethnic or sex predilection, and is classified by Orphanet as a “rare disease”, 
with an estimated prevalence of less than 1/106 within the global population 
(http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=526). 
The mutations so far identified in LS cause constitutive activation of ENaC, which is 
composed of three homologous subunits, α, β and γ, sharing around 30-40% sequence 
identity. Each subunit is encoded by a specific gene (SCNN1A, SCNN1B, and 
SCNN1G, respectively) containing 13 exons. SCNN1A is located on 12p13.31, while 
SCNN1G and SCNN1B reside within a common 400-kb fragment on human 
chromosome 16p13-p12. Each ENaC subunit consists of two transmembrane domains, a 
large extracellular loop, and short cytoplasmic amino and carboxyl termini [4-6].  
ENaC is expressed in the apical membrane of the principal cells of the aldosterone-




connecting tubule, and the entire collecting duct. ENaC, which  is highly selective for 
Na+ ions and inhibited by amiloride, mediates the rate-limiting step in Na+ absorption 
in the ASDN. The activity of ENaC depends on channel open probability (Po) and on 
the number of channels expressed at the apical membrane of ASDN principal cells. 
Aldosterone, which is the main regulator of ENaC, increases both the number of ENaCs 
expressed at the apical membrane and the channel Po [7-9].  
To our knowledge, twenty-nine LS-causing alleles have been reported to date, occurring 
in familial or sporadic cases [10-11]. Apart from γENaC N530S and αENaC C479R, 
which increase the channel Po without changing the cell surface expression of ENaC 
[11, 12], all the other mutations cluster within exon 13 of either SCNN1B or SCNN1G 
genes, and are frameshift or nonsense or missense mutations that delete or alter a 
proline-rich PY motif, corresponding to the sequence PPPXY (where X is any 
aminoacid) in the cytoplasmic C-terminus of the β or γ subunit. Of the 22 β-subunit 
mutations, 12 cause deletion of the PY motif, and 10 alter the sequence of the PY motif 
[13-23].  
The PY motif plays a fundamental role in the internalization of ENaCs. Indeed, PY 
motifs of all the three ENaC subunits are the recognition site for the ubiquitin-protein-
ligase Nedd4-2, which interacts with these motifs and ubiquitinates ENaC. 
Ubiquitination targets the ENaC for internalization and degradation, thus decreasing the 
number of ENaC expressed in the apical membrane. Mutations causing deletion or 
alteration of the PY motif prevent Nedd4-2 binding to ENaC. As a consequence, 
internalization and degradation of ENaC fail to occur, resulting in increased density of 
ENaC at the apical membrane of the ASDN. In addition to affecting the number of 




The increased ENaC activity in the apical surface of ASDN leads to a greater Na+ 
reabsorption, plasma volume expansion, high blood pressure, and consequent decrease 
in renin and aldosterone secretion. In addition, the increased Na+ reabsorption through 
ENaC generates a transepithelial lumen-negative voltage that drives K+ secretion across 
the apical membrane, resulting in hypokalaemic metabolic alkalosis [8].  
Here we analyze three previously reported families affected by LS caused by the same 
allele (βENaC P617L). The three families were native of a limited area of Italy, 
consisting of the two neighbouring Provinces of Messina (Sicily) and Reggio Calabria 
(Calabria) located on the shores of the Messina Strait, and were reportedly unrelated. 
Considering the rarity of LS, the lack of other reports of the βP617L mutation, and the 
restricted geographical area of origin shared by the three families, we checked the 
hypothesis that the three kindreds were carrying a mutation identical by descent. We 
therefore investigated, using genome-wide analyses, whether the LS-causing allele 
shared by the three probands and some of their relatives is a consequence of recurrent 
mutation or identity by descent (IBD) and, in the latter case, how many affected 
individuals should be expected, based on coalescent theory and forward simulation. 
Indeed, estimating the number of generations that separate reportedly unrelated patients, 
has important consequences on the prediction of the number of additional affected 
individuals yet to be diagnosed in a given population source. Previously, successful 
strategies were deployed to apply evolutionary inference to tackle this problem [25, 26]. 
Particularly, approaches based on coalescent theory were adopted, where the 
convergence of the alleles of a given locus to their common ancestor from an earlier 
time is used to make inferences on the evolutionary history of the examined DNA 






The data that support the findings of this study are available from the corresponding 
author upon reasonable request. Scripts from Y.D. are available here: 
https://github.com/ydiekmann/Pagani_Hypertension_2017 
Probands discovery and sampling 
Some of us (E.R., E.F., B.C., F.M.) have previously identified a novel allele of the β 
subunit of ENaC (βP617L) causing LS in a proband whose paternal line was strongly 
suspected of carrying the allele. Expression of this ENaC variant in Xenopus oocytes 
caused a three-fold increase in amiloride-sensitive Na+ current compared with wild-
type channels [15]. Later, the same group of authors found a second family carrying the 
same allele [27]. Lastly, a third family carrying the βP617L allele was recently 
identified by some other members of our current group (M.R., A.C., F.N., O.Z.) [28].  
All subjects participating in the study provided their informed consent. The study was 
approved by the Ethics Committees of Santa Maria Nuova Hospital, Reggio Emilia, and 
MultiMedica Hospital, Sesto San Giovanni, Milan, respectively. 
Genome-wide genotyping 
Genomic DNA of the following samples (A IV-1, A III-2, A II-3, B V-1, B IV-2, B IV-
3, B IV-4, B III-3, C IV-1, C III-2, C III-3, C II-2) (see Figure 1 for their family trees) 
was quantified with the Quant-iT dsDNA Broad-Range Assay Kit (Invitrogen Life 
Technologies, Carlsbad, CA, USA) and 200 ng of DNA were used to genotype 542,585 
genome-wide SNPs with the CoreExomeChip v.1.1 Array (Illumina, San Diego, CA, 
USA). A panel of 780 healthy Italian adult samples typed for the same set of markers 




showing more than 1% missing genotypes, as well as those presenting discordant 
genetic/ascertained sex (as revealed by comparison of each individual’s mean 
homozygosity rate across X-chromosome markers with the expected rate) were removed 
from subsequent analyses. Moreover, autosomal heterozygosity rate per individual was 
assessed and subjects with excessive or reduced proportion of heterozygote genotypes 
(i.e. with values exceeding ± 3 standard deviations from the mean) were filtered out. 
Further quality checks (PLINK commands –geno 0.1 –irem 0.08) and phasing were then 
performed on the entire dataset (i.e. including both healthy and disease individuals) to 
avoid batch effects. 
mtDNA and Y chromosome analyses 
The hypervariable region HVRI of the mtDNA genome and the 17 Y chromosome short 
tandem repeats profiles were analysed in individuals from the three families with LS. 
Moreover, the complete mitochondrial genomes of two probands (A IV-1 and C IV-1) 
were sequenced to confirm the haplogroup inferred from the HVSI sequence. The 
mitochondrial genomes were sequenced with the Ion PGM™ System (Life 
Technologies, GrandIsland, NY, USA) taking advantage of an optimized protocol [30]. 
Estimating tMRCA and number of carriers 
Firstly, we estimated the time to the most recent common ancestor (tMRCA) of the 
4.5Mbp haplotype encompassing the causal mutation and shared by the three probands 
using an analytical approach based on coalescent theory. The linkage map positions [31] 
corresponding to the physical chromosomal positions were converted into a 
recombination rate 𝑟 per generation using Haldane’s map function 




where 𝑑 is the genetic distance between the markers delimiting the conserved haplotype 
in Morgan. We set the effective size 𝑁. of the population that the carriers are from to //00th of the census population size for the Italian provinces of Reggio Calabria (census 
population 2014: 557,993, http://www.tuttitalia.it/calabria/provincia-di-reggio-
calabria/statistiche/censimenti-popolazione/) and Messina (census population 2014: 
645,296, http://www.tuttitalia.it/sicilia/provincia-di-messina/statistiche/censimenti-
popolazione/), however, the tMRCA estimates remain largely constant for all values of 𝑁. > 400 (data not shown). Under the assumptions of coalescent theory—most 
importantly neutrality—the probability distribution of time to the most recent common 
ancestor 𝑡 given the haplotype data 𝐷, here 𝐷 = 3, can be expressed as the distribution 
of the sum (and therefore the convolution) of independent exponential random variables 
with parameters 𝜆8 = 8(8(/:);<=));< , 𝑖 ∈ {2, … , 𝐷 } [32]. 
Pr 𝑡 𝐷 = 	 𝜆8𝑒(DEF 𝜆G𝜆G − 𝜆8|I|GJ),GK8
|I|
8J) . 
Secondly, we estimated the number of carriers today by forward simulations of a 
Wright-Fisher population. In order to model population growth over the last thousand 
years, either an exponential	𝑓 𝑡; 𝑁0, 𝑟 = 𝑁0=F:/ or a hyper-exponential model 𝑓 𝑡; 𝑁0, 𝑏, 𝑟 = 𝑁0𝑏PQR(/ was fitted to the historical demographic data of Italy 
(https://en.wikipedia.org/wiki/Demographics_of_Italy) by least squares minimisation 
(Figure S1). For fitting, 𝑁0 was set to the current census population size of Italy 
(https://en.wikipedia.org/wiki/Demographics_of_Italy) (time 𝑡 therefore taking negative 
values backwards in time) and later scaled down to the current joint census population 




single allele at a time point in the past sampled from the distribution of tMRCA 
established above, multiplied with a generation time sampled uniformly between 25 and 
31 years. Finally, we conditioned the resulting distribution of number of carriers to 
values greater or equal than 3, accounting for the prior knowledge from direct 
observation of three carriers. 
RESULTS 
Sequencing analysis had previously detected a heterozygous C to T allele at codon 617 
in exon 13 of SCNN1B in A IV-1, B V-1, B IV-2, B IV-3, B III-3, C IV-1, C III-2, C 
III-3, C II-2. Therefore, screening the three probands’ relatives led to the identification 
of six more carriers of the same allele. The mutant allele is predicted to replace the 
second proline with leucine in the sequence 616PPPXY620 (PY motif) of the β subunit (β 
P617L mutation). Each of the three families was characterized by an early onset of 
hypertension and premature cardiovascular events in several members across 
generations, which is consistent with an autosomal-dominant pattern of inheritance 
(Figure 1).  
Age at presentation of hypertension ranged from 11 to 31 years. The time lapse between 
the ascertainment of hypertension and diagnosis of LS was remarkably variable among 
our LS patients, from a few years to decades, confirming that LS may be misdiagnosed 
and undertreated. Severity of hypertension among our LS patients ranged from mild to 
severe. Plasma potassium levels were low in the probands of family A and C, but 
completely normal in the proband’s sister of family C and in family B. The proband’s 
sister of family C (C III-3) was normotensive at the beginning of our research, but 
developed hypertension during the preparation of our manuscript. Low plasma level of 




belonging to the three families. Treatment with amiloride at a daily dose ranging from 5 
to 20 mg resulted in normalization of blood pressure, correction of hypokalaemia or 
maintenance of normal potassium levels in those with pre-treatment normokalaemia, 
and increase in plasma levels of renin and aldosterone (Table 1). 
Comparison of mtDNA and Y chromosome showed different lineages between the lines 
(either maternal or paternal) carrying the β-P617L mutation (Table 2). However, the 
probands’ mtDNA haplotypes in families A and C are typical of people of Sicilian-
Calabrian descent, suggesting a localized geographic origin in the provinces of Messina 
(Sicily, Italy) and Reggio Calabria (Calabria, Italy) based also on surname localization 
(data not shown to protect the anonymity of the probands). We therefore compared the 
total proportion of shared genome (using the PLINK –genome function) between pairs 
of affected samples and between affected and control samples to uncover relatedness at 
the genomic level. The proportion of genome shared by IBD in pairs of affected 
samples each belonging to a different family was comparable to the proportion of 
genome shared between these and the healthy controls (no comparison was above the 
top 1% of the empirical distribution). This confirms that the three LS families are not 
closely related at a genomic level, consistently with the mtDNA and Y chromosome 
results. 
However, on closer inspection, the shared LS-causing allele tagged a genomic 
haplotype shared by all the nine carriers, which spans 4.5 Mbps on chromosome 16 and 
encompasses a smaller “core” haplotype also detected among the healthy control 
samples (Figure S2). Given its length, such a haplotype is unlikely to have arisen by 
chance in all three families and is therefore best explained as the three families sharing 




of this haplotype, and in turn used this date to estimate how many un-sampled carriers 
to expect in the same population. 
As a starting point we selected the population of Messina and Reggio Calabria (shown 
to be a continuum from a biodemographic viewpoint [33], total census size ~1.2 
Million) as the source population of the three cases. The tMRCA for the disease allele-
associated haplotype in these 3 families was estimated to have lived 13 (95% CI: 1.4 – 
37.6) generations ago (Figure 2a). By performing forward simulations conditioned on at 
least 3 carriers being present in today’s generation we estimate that 20 (95% highest 
posterior density (HPD): 3 - 69) carriers are present in the region of origin of the 
affected individuals (Figure 2b), 17 in addition to the already sampled probands and 
their relatives. This number is even larger (99, 95% HPD: 3 - 193) when using an 
exponential rather than a hyper-exponential function to model population growth in 
Southern Italy. Therefore, we conservatively estimate the prevalence of the Liddle 
syndrome due to β-P617L mutation to be 20/1,200,000=1.67 x 10-5 (95% HPD: 2.5 x 
10-6 - 5.75 x 10-5), which is at least 17 times higher than the estimated prevalence of <1 
x 10-6 worldwide.  
 
DISCUSSION 
Our findings show that, when ascertaining reportedly unrelated individuals belonging to 
a circumscribed population for the presence of a rare disease, the chances of discovering 
cryptic relatedness in the form of a long shared haplotype at the disease-causing locus 
are high. In the present study we report that the three probands shared a common 




From a clinical viewpoint, our study confirms the variable expressivity of LS with 
regard to age at presentation, degree of hypertension, and plasma potassium 
concentration, despite sharing the same causative allele. Both blood pressure and 
plasma potassium values can vary greatly among patients within the same pedigree, or 
unrelated patients with the same allele, presumably as a result of both allelic variants of 
other genes and different sodium and potassium intakes, which may modify the effects 
of the mutant alleles [3, 22, 27]. On the contrary, reduced plasma levels of renin 
associated with low- or normal values of plasma aldosterone are a common finding in 
LS patients. One carrier of the β P617L allele (C IV-1) did not exhibit the LS 
phenotype. However, he was newly born (now 4 years old). Since LS usually manifests 
itself between the ages of 10 and 30 years, he could develop LS in the future. 
Alternatively, he could be spared from developing LS, since LS alleles are incompletely 
penetrant, even within the same kin [3]. Since this subject is actually at risk of LS, we 
have planned periodic monitoring of his blood pressure, plasma potassium values, and 
urinary sodium excretion (in order to check his intake of sodium).  
Though LS is considered a very rare condition, its prevalence in very large cohorts of 
hypertensives has not been investigated to date. However, in two different cohorts of 
330 and 766 Chinese patients with early-onset hypertension, the prevalence of LS 
genetically confirmed turned out to be 1.5% and 0.9%, respectively. Moreover, genetic 
screening of the probands’ relatives identified many more cases with LS, as expected 
from the Mendelian dominant nature of the disease [34, 35].   
These findings suggest that the prevalence of LS may not be as low as commonly 
reported. Moreover, one of the above studies [34] may have failed to identify some LS 




testing. Indeed, plasma potassium concentration may range from severe hypokalaemia 
to normal values both among LS patients belonging to the same kin and among 
reportedly unrelated kin carrying the same allele [3, 27], as shown in the present study. 
This variability of plasma potassium concentration is reminiscent of other conditions 
characterized by increased activity of ENaC, in primis primary aldosteronism. Indeed, 
screening of hypertensives for primary aldosteronism regardless of plasma potassium 
values has considerably increased the prevalence of this condition among hypertensives 
from less than 1% to more than 10%, and showed that the majority of the patients are 
actually normokalaemic [36]. By contrast, LS is currently considered exclusively in 
hypokalaemic hypertensives, while normokalaemic patients with LS are identified only 
following the genetic screening of the relatives of hypokalaemic probands. Thus, 
existing approaches may fail to diagnose and appropriately treat many normokalaemic 
patients with LS. Therefore, LS should be taken into account in all patients with early-
onset hypertension, regardless of the plasma potassium concentration. Moreover, LS 
should be considered even in young hypertensives without a family history of early-
onset hypertension, since de novo mutations may be responsible for sporadic cases of 
LS [20, 37, 38].  
More extensive searching for, and earlier diagnosis of LS patients is justified for several 
reasons. Firstly, patients with misdiagnosed LS are at high risk of both cerebrovascular 
and cardiovascular events, including sudden death, and are unresponsive to both 
conventional antihypertensive drugs and MR-antagonists. Secondly, in many patients 
diagnosis of LS is delayed by many years, and many more patients remain undiagnosed 
in their lifetime. Thirdly, screening of the probands’ relatives often leads to the 




treated. Lastly, ENaC blockers (amiloride and triamterene) together with dietary salt 
restriction are impressively efficient in both reversing the clinical manifestations and 
preventing the severe complications of LS.  
CONCLUSIONS 
With the present study, we infer the evolutionary history of the disease-causing allele 
detected in all three affected families, building on an approach developed for another 
successful prediction of under-diagnosed cases of a rare disease [25, 26].  
PERSPECTIVES 
We predict that a considerable number of undiagnosed cases may reside in the area of 
origin of these three families, which constitutes between a 17- and 82-fold increase in 
the prevalence (depending on the assumed underlying demographic model). Our results 
suggest that evolutionary approaches combined with clinical data may increase the 
accuracy of epidemiological prediction, at least in original populations of circumscribed 
geographical areas, and contribute to the understanding of the prevalence and hopefully 
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NOVELTY AND SIGNIFICANCE 
What is new? 
Genome-wide analysis of three kindreds from southern Italy with the same mutation 
responsible for Liddle syndrome (LS) and without a family relationship between each 
other showed a common haplotype encompassing the pathogenic allele. An 
evolutionary approach based on coalescent analysis showed that the three families 
inherited the mutant allele from a common ancestor who lived about 13 generations 
earlier and that several undiagnosed patients with the same LS mutation live in the same 
area of origin. 
What is relevant? 
Hypertension due to Liddle syndrome may be more common in southern Italy than 
elsewhere.  
Summary 
Genome-wide analysis supplemented by coalescent analysis allowed us to infer the 
evolutionary history of a LS mutation shared by three kindreds and predict the 







Figure 1. Pedigrees of the three families (A, B, C) carrying the βENaC P617L 
mutation. Squares indicate males and circles females. Deceased members are indicated 
with diagonal lines. The individuals submitted to genetic testing are marked with an 
asterisk. Individuals with proven βENaC P617L mutation in the genetic analysis are 
indicated as filled black symbols. Individuals with either early hypertension or 
premature cardiovascular events suggestive of Liddle syndrome are indicated as filled 






Figure 2. Demographic simulations. Estimated tMRCA for the three carriers of the LS 
haplotype (A). Estimated number of carriers of the LS haplotype in the population of 
















Table 1. Clinical characteristics of the examined subjects of the three pedigrees 
carrying the βP617L mutation  
HT, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; Tx, 
treatment with amiloride; PRA, plasma renin activity in sitting position; p[Aldo], 
plasma aldosterone in sitting position. The patients are indicated as in the Figure 1. B 
IV-2 declined treatment and follow-up. C IV-1 was newly born at the time of genetic 






A IV-1 B V-1 B IV-2 B IV-3 B III-3 C IV-1 C III-2 C III-3 C II-2 
Sex  M M M F F M F F F 
Age at genetic 
analysis, ys  













127/70 128/84 - 122/80 130/76 - 125/80 - 148/94 
[K+], mmol/L 2.8 4.6 4.7 4.3 3.9 4.5 3.0 3.8 - 
Post-Tx [K+] 4.3 5.2 - 4.2 4.4 - 4.1 - - 
Pre-Tx PRA, 
ng/ml/h 
0.1 0.3 0.3 0.8 0.8 - 0.1 0.2 - 
Post-Tx PRA, 
ng/ml/h 
0.8 2.5 - 6.4 2.7  3.0 - - 
Pre-Tx 
p[Aldo], ng/dL 
<1.0 3.0 1.5 1.5 3.0 - <1.0 3.4 - 
Post-Tx 
p[Aldo], ng/dL 









Subjects* mtDNA HVRI haplotype/lineage Y STRs** 
haplotype/lineage 
A IV-1 16129, 16183, 16189, 16193insC, 16223, 16249, 
16311/M1a 
14, 12, 22, 28, 15, 14, 
12/14, 13, 10, 11, 22, 
11, 11, 16, 10, 20/I1 
A III-2 16130, 16183, 16189, 16193insC, 16223, 16249, 
16311/M1a 
 
A II-3 16223, 16270, 16292/W  
B V-1 16147, 16183, 16189, 16193insC, 16240, 16270/U5b 15, 13, 23, 30, 17.2, 
13, 12/17, 12, 10, 12, 
20, 11, 11, 14, 10, 
20/J1 
B IV-3 16148, 16183, 16189, 16193insC, 16240, 16270/U5b  
B IV-2 16149, 16183, 16189, 16193insC, 16240, 16270/U5b  
B III-3 16150, 16183, 16189, 16193insC, 16240, 16270/U5b  
B IV-4 rCRs/H 15, 13, 23, 30, 17.2 
13, 12/17, 12, 10, 12, 
20, 11, 11, 14, 10, 
20/J1 
C IV-1 146, 152, 247, 489, 769, 813, 825, 1018, 2758, 2885, 
3594, 4104, 4312, 6446, 6473, 6671, 6680, 7146, 
7256, 7521, 8468, 8655, 10400, 10664, 10688, 
10810, 10915, 11257, 11914, 12403, 12950, 13105, 
13276, 13506, 13637, 13650, 14110, 14783, 15043, 
15301, 16187, 16223, 16230, 16249, 16278/M1a3a 
16, 13, 23, 29, 16, 13, 
13-17, 13, 10, 10, 23, 
11, 11, 15, 9, 19 
C III-2 146, 152, 247, 489, 769, 813, 825, 1018, 2758, 2885, 
3594, 4104, 4312, 6446, 6473, 6671, 6680, 7146, 
7256, 7521, 8468, 8655, 10400, 10664, 10688, 
10810, 10915, 11257, 11914, 12403, 12950, 13105, 
13276, 13506, 13637, 13650, 14110, 14783, 15043, 
15301, 16187, 16223, 16230, 16249, 16278/M1a3a 
 
C III-3 146, 152, 247, 489, 769, 813, 825, 1018, 2758, 2885, 
3594, 4104, 4312, 6446, 6473, 6671, 6680, 7146, 
7256, 7521, 8468, 8655, 10400, 10664, 10688, 
10810, 10915, 11257, 11914, 12403, 12950, 13105, 
13276, 13506, 13637, 13650, 14110, 14783, 15043, 
15301, 16187, 16223, 16230, 16249, 16278/M1a3a 
 
C II-2 146, 152, 247, 489, 769, 813, 825, 1018, 2758, 2885, 
3594, 4104, 4312, 6446, 6473, 6671, 6680, 7146, 
7256, 7521, 8468, 8655, 10400, 10664, 10688, 
10810, 10915, 11257, 11914, 12403, 12950, 13105, 
13276, 13506, 13637, 13650, 14110, 14783, 15043, 
15301, 16187, 16223, 16230, 16249, 16278/M1a3a 
 
C II-1  14, 13, 24, 29, 16, 14, 
11-14, 12, 10, 12, 25, 




Table 2 Mitochondrial haplogroups and Y chromosome STR profile in subjects 
belonging to the three families with LS (see Figure 1).  
*indicated as in the Figure 1 
**n° of alleles for the following STRs loci: DYS456, DYS389I, DYS390, DYS389II, 
DYS458, DYS19, DYS385a/b, DYS393, DYS391, DYS439, DYS635, DYS392, Y 
GATA H4, DYS437, DYS438, DYS448. mtDNA, mithocondrial DNA; STR, short 
tandem repeat; rCRS, revised Cambridge Reference Sequence 
 
